Skip to content

The Use of Oral Steroids in the Treatment of Cellulitis

Utility of Prednisone in the Treatment of Cellulitis

Status
Withdrawn
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00893048
Enrollment
0
Registered
2009-05-05
Start date
2010-01-15
Completion date
2010-08-31
Last updated
2017-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cellulitis, Erysipelas

Keywords

prednisone, cellulitis, erysipelas, steroids, oral

Brief summary

The prevalence of cellulitis in society is very high, as much as 3% of visits to Emergency Departments are for the treatment of this disease. The treatment of cellulitis varies depending on the severity. Low severity cases are treated with pain control and antibiotics by mouth and high severity are treated with antibiotics intravenously and pain control. The investigator's hypothesis is to see if the addition of steroids, which are known to decrease inflammation, will decrease the length of the disease process. If so, it will decrease the length of stay if IV antibiotics are needed, it will decrease duration of days out of work and decrease the overall pain control required and therefore patient satisfaction.

Detailed description

The incidence of cellulitis is about 24.6 cases per 1000 person-years, which is an estimate, since cellulitis is not a reportable disease. In some Emergency Departments up to 3% of visits are for cellulitis. Depending on the severity of the disease, some are treated as outpatients, and others are admitted for IV antibiotics. In some Emergency Departments cases of cellulitis are treated in an observation area for 23 hours with doses of IV antibiotics. My proposed research is to see if the addition of one dose of prednisone the treatment will decrease the inflammatory reaction enough to decrease length of stay and treatment and increase patient satisfaction.

Interventions

DRUGPrednisone

Prednisone, 60 mg, one time at time of diagnosis

DRUGPlacebo Oral Tablet

Placebo

Sponsors

Milton S. Hershey Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* 18-70 years old * signs/symptoms of cellulitis

Exclusion criteria

* steroid use in last 2 weeks * hx of adrenal insufficiency * suspicion for dvt or abcess * systemic signs of sepsis * ICU admission

Design outcomes

Primary

MeasureTime frame
Time to cellulitis resolving48 hours after initiation of treatment

Secondary

MeasureTime frame
Length of stayafter treatment completed

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026